Drug discovery firm’s leukaemia treatment breakthrough

DRUG discovery and development company Redx Pharma has unveiled a major breakthrough in treatment for leukaemia and other blood cancers.

The listed company, based at Alderley Park in Cheshire, says it has reached pre-clinical proof of concept on a reversible BTK inhibitor, which offers “exciting potential” to treat Chronic Lymphocytic Leukaemia (CLL), one of the most common types of leukaemia in adults, not usually curable.

BTK (Bruton’s Tyrosine Kinase) is an important enzyme in the B-cell r... You can carry on reading TheBusinessDesk.com for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...